238 related articles for article (PubMed ID: 35978174)
1. Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE).
de Baere T; Ronot M; Chung JW; Golfieri R; Kloeckner R; Park JW; Gebauer B; Kibriya N; Ananthakrishnan G; Miyayama S
Cardiovasc Intervent Radiol; 2022 Oct; 45(10):1430-1440. PubMed ID: 35978174
[TBL] [Abstract][Full Text] [Related]
2. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
[TBL] [Abstract][Full Text] [Related]
3. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response.
Hu J; Maybody M; Cao G; Wang X; Chen H; Zhu X; Yang R; Wang X
Cancer Imaging; 2016 Oct; 16(1):32. PubMed ID: 27716376
[TBL] [Abstract][Full Text] [Related]
4. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
[TBL] [Abstract][Full Text] [Related]
5. Value of Latest-generation Cone-beam Computed Tomography for Post Lipiodol-embolization Imaging in Hepatic Transarterial Chemoembolization in Comparison with Multi-detector Computed Tomography.
Alizadeh LS; Koch V; Vogl TJ; Yel I; Gruenewald L; Albrecht MH; Herrmann E; von Knebel-Doeberitz PL; Booz C
Acad Radiol; 2022 Jul; 29(7):e109-e118. PubMed ID: 34598867
[TBL] [Abstract][Full Text] [Related]
6. Early prediction of 1-year tumor response of hepatocellular carcinoma with lipiodol deposition pattern through post-embolization cone-beam computed tomography during conventional transarterial chemoembolization.
Tsai YC; Shih JH; Hwang HE; Chiu NC; Lee RC; Tseng HS; Liu CA
Eur Radiol; 2021 Oct; 31(10):7464-7475. PubMed ID: 33765160
[TBL] [Abstract][Full Text] [Related]
7. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
[TBL] [Abstract][Full Text] [Related]
8. Chemical Shift MRI Monitoring of Chemoembolization Delivery for Hepatocellular Carcinoma: Multicenter Feasibility of Initial Clinical Translation.
Gordon AC; Lewandowski RJ; Li W; Zhong X; Kannengiesser SAR; Miller FH; Salem R; Rilling WS; Larson AC; White SB
Radiol Imaging Cancer; 2023 May; 5(3):e220019. PubMed ID: 37233207
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of Vascular Lake Phenomenon Before Embolization for the Prediction of Lipiodol Uptake for Intermediate-Stage Hepatocellular Carcinoma Patients that Underwent cTACE.
Hu B; Zhong BY; Zhang L; Dai C; Li W; Shen J; Huang P; Zhang S; Li Z; Ni CF
Cardiovasc Intervent Radiol; 2020 Oct; 43(10):1460-1467. PubMed ID: 32500251
[TBL] [Abstract][Full Text] [Related]
10. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
11. Improved Local Tumor Control and Survival Rates by Obtaining a 3D-Safety Margin in Superselective Transarterial Chemoembolization for Small Hepatocellular Carcinoma.
Kattipatanapong T; Nishiofuku H; Tanaka T; Sato T; Masada T; Tatsumoto S; Matsumoto T; Kichikawa K
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):423-433. PubMed ID: 31720806
[TBL] [Abstract][Full Text] [Related]
12. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
[TBL] [Abstract][Full Text] [Related]
13. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
14. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma.
Langenbach MC; Vogl TJ; Said G; Scholtz JE; Hammerstingl R; Gruber-Rouh T
Cancer Biother Radiopharm; 2024 Apr; 39(3):196-202. PubMed ID: 33481646
[No Abstract] [Full Text] [Related]
15. Dual-phase Cone-beam CT-based Navigation Imaging Significantly Enhances Tumor Detectability and Aids Superselective Transarterial Chemoembolization of Liver Cancer.
Yao X; Yan D; Jiang X; Li X; Zeng H; Liu D; Li H
Acad Radiol; 2018 Aug; 25(8):1031-1037. PubMed ID: 29398432
[TBL] [Abstract][Full Text] [Related]
16. Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization.
Bannangkoon K; Hongsakul K; Tubtawee T
BMC Gastroenterol; 2021 Nov; 21(1):419. PubMed ID: 34749658
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T
Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185
[TBL] [Abstract][Full Text] [Related]
18. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
19. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
Chen S; Peng Z; Zhang Y; Chen M; Li J; Guo R; Li J; Li B; Mei J; Feng S; Kuang M
Radiology; 2021 Mar; 298(3):680-692. PubMed ID: 33464183
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
